Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down – Should You Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped down prior to trading on Friday . The stock had previously closed at $30.40, but opened at $27.20. Capricor Therapeutics shares last traded at $26.1710, with a volume of 432,139 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Finally, Piper Sandler reissued an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.30.

Capricor Therapeutics Trading Down 13.1%

The company has a market cap of $1.53 billion, a PE ratio of -11.45 and a beta of 0.39. The firm’s 50-day simple moving average is $30.18 and its two-hundred day simple moving average is $28.43.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, analysts predict that Capricor Therapeutics, Inc. will post -0.75 EPS for the current year.

Insider Activity

In related news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer owned 8,223 shares of the company’s stock, valued at $260,669.10. The trade was a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the completion of the transaction, the director owned 7,529 shares in the company, valued at approximately $240,928. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 173,429 shares of company stock worth $5,329,440. Company insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Large investors have recently made changes to their positions in the business. Glenmede Trust Co. NA increased its stake in shares of Capricor Therapeutics by 13.2% in the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after acquiring an additional 4,240 shares during the period. Bank of America Corp DE boosted its holdings in Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after purchasing an additional 361,664 shares during the last quarter. Stempoint Capital LP boosted its holdings in Capricor Therapeutics by 110.6% in the first quarter. Stempoint Capital LP now owns 37,592 shares of the biotechnology company’s stock valued at $1,143,000 after purchasing an additional 19,739 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Capricor Therapeutics during the 1st quarter worth about $687,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Capricor Therapeutics during the 1st quarter worth about $3,463,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.